Pharmaceuticals Global On demand · 24-48h

Global Circadian Rhythm Sleep Treatment Market Strategic Research Report

Global Circadian Rhythm Sleep Treatment Market Strategic Res…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Circadian Rhythm Sleep Treatment Market
$1.03B2025
5.9%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Drug Therapy, Light Therapy

By Application: Delayed Sleep Phase Syndrome (DSPS), Advanced Sleep Phase Syndrome (ASPS), Irregular Sleep-Wake Disorder (ISWD), Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Koninklijke Philips, Luminette, Sleepace, PEGASI, Teva Pharmaceuticals, Takeda Pharmaceutical, NBTY, Vicks (Procter & Gamble), Natrol, Nature Made (Pharmavite), Jameison, GNC, By-Health

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 109 pages
Market size 2025
$1.03B
Billion USD
Forecast CAGR
5.9%
2025-2032
Forecast 2032
$1.5B
Projected
Regiões
5
Asia Pacific · Latin America · MEA · Europe · North America

Visão geral

Scope of the Report

The global Circadian Rhythm Sleep Treatment market size is predicted to grow from US$ 1,035 million in 2025 to US$ 1,535 million in 2032; it is expected to grow at a CAGR of 5.9% from 2026 to 2032.

Circadian rhythm disorders are disruptions in a patient's internal clock that regulates a variety of biological processes, which makes it difficult to follow normal sleep patterns. The circadian rhythm disorders include: Delayed sleep-wake phase, Advanced sleep-wake phase, Irregular sleep-wake rhythm, Non-24-hour sleep-wake rhythm, Shift work, Jet lag. The most common treatments for circadian rhythm disorders are healthy lifestyle changes, bright light therapy, and melatonin. It is aim to reset people's sleep-wake rhythm to align with the environment.

The global circadian rhythm sleep treatment market is set for continued growth driven by increased awareness, advancements in treatment options, and technological innovations. The emphasis on personalized medicine, improved diagnostic tools, and a growing focus on sleep health and wellness are key factors contributing to market expansion. However, challenges such as regional disparities in awareness and the cost of advanced treatments remain. Ongoing research and development will play a crucial role in shaping the future of the market.Global key players of circadian rhythm sleep treatment include Takeda Pharmaceutical, NBTY, Nature Made (Pharmavite) and Vicks (Procter & Gamble), etc. The top four players hold a share over 40%. In terms of product type, drug therapy is the largest segment, occupied for a share of approximately 80%, and in terms of application, delayed sleep phase syndrome has a share about 50%.

This report presents a comprehensive overview of the global Circadian Rhythm Sleep Treatment market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Drug Therapy
  • Light Therapy

Segment by players, this report covers

  • Koninklijke Philips
  • Luminette
  • Sleepace
  • PEGASI
  • Teva Pharmaceuticals
  • Takeda Pharmaceutical
  • NBTY
  • Vicks (Procter & Gamble)
  • Natrol
  • Nature Made (Pharmavite)
  • Jameison
  • GNC
  • By-Health

Segment by Application

  • Delayed Sleep Phase Syndrome (DSPS)
  • Advanced Sleep Phase Syndrome (ASPS)
  • Irregular Sleep-Wake Disorder (ISWD)
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Circadian Rhythm Sleep Treatment market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Delayed Sleep Phase Syndrome (DSPS), Advanced Sleep Phase Syndrome (ASPS), Irregular Sleep-Wake Disorder (ISWD) evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Circadian Rhythm Sleep Treatment Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 5.9%
Regional growth momentum
Market share by segment
Key metrics
Base value
$1.03B
2025
Forecast
$1.5B
2032
CAGR
5.9%
2025–2032
Regiões
5
global
Key companies
Koninklijke PhilipsLuminetteSleepacePEGASITeva PharmaceuticalsTakeda PharmaceuticalNBTYVicks (Procter & Gamble)
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Drug TherapyLight Therapy
By Application
Delayed Sleep Phase Syndrome (DSPS)Advanced Sleep Phase Syndrome (ASPS)Irregular Sleep-Wake Disorder (ISWD)Others

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Drug Therapy
  • 3.1.3 Light Therapy
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Delayed Sleep Phase Syndrome (DSPS)
  • 4.1.3 Advanced Sleep Phase Syndrome (ASPS)
  • 4.1.4 Irregular Sleep-Wake Disorder (ISWD)
  • 4.1.5 Others
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Koninklijke Philips
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Luminette
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Sleepace
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 PEGASI
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Teva Pharmaceuticals
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Takeda Pharmaceutical
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 NBTY
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Vicks (Procter & Gamble)
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Natrol
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Nature Made (Pharmavite)
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Jameison
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 GNC
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 By-Health
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Circadian Rhythm Sleep Treatment market?
The global Circadian Rhythm Sleep Treatment market is estimated at US$ 1.03 billion in 2025 (base year) and is projected to reach US$ 1.53 billion by 2032.
How fast is the Circadian Rhythm Sleep Treatment market expected to grow?
The market is expected to grow at a CAGR of 5.9% from 2026 to 2032, expanding from US$ 1.03 billion in 2025 to US$ 1.53 billion in 2032, roughly 1.5 times its base-year value.
What does the Circadian Rhythm Sleep Treatment market cover?
Circadian rhythm disorders are disruptions in a patient's internal clock that regulates a variety of biological processes, which makes it difficult to follow normal sleep patterns. The circadian rhythm disorders include: Delayed sleep-wake phase, Advanced sleep-wake phase, Irregular sleep-wake rhythm, Non-24-hour sleep-wake rhythm, Shift work, Jet lag. The most common treatments for circadian rhythm disorders are healthy lifestyle changes, bright light therapy, and melatonin.
What are the main segments of the Circadian Rhythm Sleep Treatment market by type?
By type, the market is segmented into Drug Therapy and Light Therapy.
Which applications drive demand in the Circadian Rhythm Sleep Treatment market?
Key applications covered include Delayed Sleep Phase Syndrome (DSPS), Advanced Sleep Phase Syndrome (ASPS), Irregular Sleep-Wake Disorder (ISWD) and Others.
Who are the key players in the Circadian Rhythm Sleep Treatment market?
Key players profiled include Koninklijke Philips, Luminette, Sleepace, PEGASI, Teva Pharmaceuticals, Takeda Pharmaceutical, NBTY and Vicks (Procter & Gamble), among 13 companies covered in total.
Which regions and countries are covered for Circadian Rhythm Sleep Treatment?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Circadian Rhythm Sleep Treatment market?
The global circadian rhythm sleep treatment market is set for continued growth driven by increased awareness, advancements in treatment options, and technological innovations.
What challenges does the Circadian Rhythm Sleep Treatment market face?
However, challenges such as regional disparities in awareness and the cost of advanced treatments remain.
Who should buy the Circadian Rhythm Sleep Treatment market report?
The report is intended for manufacturers and solution providers, distributors and end users in Delayed Sleep Phase Syndrome (DSPS), Advanced Sleep Phase Syndrome (ASPS) and Irregular Sleep-Wake Disorder (ISWD), investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Circadian Rhythm Sleep Treatment market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from US$ 3.500,00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.